Park Avenue Securities’s Pfizer PFE Stock Holding History

Park Avenue Securities’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.32M	Sell	220,927 -41,047	-16%	-$1.07M	0.03%	367
2026 Q1	$7.36M	Buy	261,974 +24,011	+10%	+$639K	0.06%	248
2025 Q4	$5.92M	Buy	237,963 +41,031	+21%	+$1.03M	0.05%	276
2025 Q3	$5.02M	Buy	196,932 +39,882	+25%	+$984K	0.04%	326
2025 Q2	$3.81M	Buy	+157,050	New	+$3.66M	0.04%	330
2025 Q1	–	Sell	-106,050	Closed	-$2.81M	–	1433
2024 Q4	$2.81M	Buy	106,050 +10,824	+11%	+$294K	0.03%	364
2024 Q3	$2.76M	Sell	95,226 -15,191	-14%	-$443K	0.03%	347
2024 Q2	$3.09M	Sell	110,417 -849	-0.8%	-$23.4K	0.04%	300
2024 Q1	$3.09M	Sell	111,266 -23,254	-17%	-$645K	0.04%	288
2023 Q4	$3.87M	Sell	134,520 -16,319	-11%	-$493K	0.05%	218
2023 Q3	$5M	Sell	150,839 -3,142	-2%	-$111K	0.08%	160
2023 Q2	$5.65M	Sell	153,981 -19,422	-11%	-$756K	0.09%	150
2023 Q1	$7.08M	Buy	173,403 +9,052	+6%	+$391K	0.12%	113
2022 Q4	$8.42M	Buy	164,351 +19,925	+14%	+$955K	0.15%	93
2022 Q3	$6.32M	Buy	144,426 +3,665	+3%	+$178K	0.13%	103
2022 Q2	$7.38M	Buy	140,761 +849	+0.6%	+$43.3K	0.14%	95
2022 Q1	$7.24M	Buy	139,912 +12,329	+10%	+$640K	0.13%	95
2021 Q4	$7.53M	Buy	127,583 +20,291	+19%	+$1.01M	0.13%	92
2021 Q3	$4.62M	Sell	107,292 -1,445	-1%	-$64K	0.09%	115
2021 Q2	$4.26M	Buy	108,737 +8,506	+8%	+$331K	0.09%	114
2021 Q1	$3.63M	Buy	100,231 +4,330	+5%	+$154K	0.09%	118
2020 Q4	$3.53M	Sell	95,901 -6,438	-6%	-$236K	0.1%	96
2020 Q3	$3.56M	Buy	102,339 +8,118	+9%	+$285K	0.12%	76
2020 Q2	$2.92M	Buy	+94,221	New	+$3.2M	0.11%	78
2020 Q1	–	Sell	-83,967	Closed	-$3.12M	–	516
2019 Q4	$3.12M	Buy	83,967 +15,815	+23%	+$563K	0.13%	68
2019 Q3	$2.32M	Buy	+68,152	New	+$2.48M	0.11%	73
2019 Q2	–	Sell	-58,433	Closed	-$2.38M	–	413
2019 Q1	$2.38M	Buy	+58,433	New	+$2.34M	0.13%	57
2017 Q3	–	Sell	-6,611	Closed	-$243K	–	202
2017 Q2	$243K	Buy	+6,611	New	+$208K	0.03%	173
2016 Q3	–	Sell	-12,030	Closed	-$406K	–	86
2016 Q2	$406K	Buy	+12,030	New	+$384K	0.07%	48

Other funds holding PFE

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return

Park Avenue Securities's PFE Position: Q2 2026 in Review

Park Avenue Securities reduced its Pfizer (PFE) stake by 16% in Q2 2026, selling an estimated $1.07M and leaving 220,927 shares worth $5.32M. The position accounts for 0.03% of the portfolio, ranked #367.

Park Avenue Securities first reported a position in PFE in Q2 2016 and has held it in 29 quarters since. The position peaked at $8.42M in Q4 2022. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Park Avenue Securities held 220,927 shares of Pfizer worth $5.32M as of Q2 2026.
Park Avenue Securities sold 41,047 Pfizer shares in Q2 2026, an estimated $1.07M.
Pfizer made up 0.03% of Park Avenue Securities's portfolio in Q2 2026, its #367 holding.
Park Avenue Securities first reported a position in Pfizer in Q2 2016 and has held it in 29 quarters since.
Park Avenue Securities's Pfizer position peaked at $8.42M in Q4 2022.
900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.